Actively Recruiting
Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome
Led by zhang shoulong · Updated on 2023-03-07
50
Participants Needed
1
Research Sites
247 weeks
Total Duration
On this page
Sponsors
Z
zhang shoulong
Lead Sponsor
J
Jinan Military General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
CAR T-cell therapy is a promising innovative therapy for hematological malignancies. Immune effectors cells-associated neurotoxicity syndrome (ICANS) is a significant complication of CAR therapy. The goal of this study is to understand what brain mechanisms become disrupted when patients experience ICANS. The study will test the hypothesis that cerebrospinal fluid catecholamines and multimodal magnetic resonance imaging are affected in this disorder. To test this hypothesis, the study will measure cerebrospinal fluid catecholamines in ICANS patients and evaluate brain magnetic resonance imaging for these participants. This study may contribute to knowledge about brain biomarkers and imaging of ICANS, which will greatly aid in ICANS detection and prevention.
CONDITIONS
Official Title
Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects must be 18 years of age or older at signing of informed consent
- Subjects are scheduled to receive CAR T-cell treatment
You will not qualify if you...
- Refusal to sign the informed consent
- Subjects having previously been treated with CAR-T therapy
- Subjects with clinically significant active bleeding, history of intracranial bleeding, or risk for intracranial bleeding
- Subjects presenting primary CNS lymphoma
- Pacemaker or other implanted electrical device incompatible with the MR environment
- Subjects with a neurodegenerative disease such as Parkinson's disease or Alzheimer's disease
- Subjects with previous or evolving neurological pathology
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
980th Hospital
Shijiazhuang, Hebei, China
Actively Recruiting
Research Team
S
Shoulong Zhang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here